New Delhi: Drug firm Cadila Healthcare reported a 32.48 percent rise in its consolidated net profit to Rs 503.3 crore for the second quarter ended September 30, mainly on account of robust sales in the US and India.
The company had posted a net profit of Rs 379.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a BSE filing.
Consolidated total revenue from operations also rose to Rs 3,234 crore for the quarter under consideration as against Rs 2,403.5 crore in the same period a year ago.
The Indian formulations business also grew by 15 percent, excluding the excise duty, to Rs 895 crore, it added.
“During the quarter, the company launched four new products in the US, including Mesalamine delayed release 1.2 g tablets (generic version of Lialda) with a 180 days exclusivity,” Cadila Healthcare said.